Specialty Pharmacy

Eligible patients in the APOLLO study had RRMM and received more than or equal to 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI) and had responded to prior treatment and progressed on or after their last regimen.

AMG 701 is a bi-specific T-cell engager molecule being investigated for relapsed or refractory heavily pre-treated multiple myeloma.

Melflufen plus dexamethasone as a triple regimen with bortezomib and daratumumab in patients with heavily pretreated relapsed or refractory multiple myeloma with poor prognostic factors was well-tolerated.

Talquetamab is a bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

Multiple myeloma is characterized by expression of the cell surface BCMA, making this a target for therapeutic intervention with REGN5458.

The combinations also demonstrated promising clinical activity, even among patients refractory to the last prior regimen and previously exposed to IMiD agents, proteasome inhibitors (PIs), and CD38 antibodies.

New research identifies patients most at risk of continuing problems with medulloblastoma, which can be applied immediately in medical clinics.

Study indicates pure CBD was able to reduce cell viability in 3 of the 6 cell lines and that this effect was cell line specific rather than specific to certain cancers.

Five oral presentations will include data on the use of gilteritinib, either as monotherapy or in combination, across the spectrum of patients with acute myeloid leukemia with a positive FLT3 mutation.

Despite the COVID-19 pandemic, several promising drugs are expected to hit the market in late 2020 and early 2021.

Further, the findings suggest that cancer survivors are also likely to be at an increased risk of severe coronavirus disease 2019 (COVID-19) outcomes, given that both influenza and COVID-19 are both epidemic respiratory viruses.

FDA grants fast track designation to irinotecan liposome injection (Onivyde; MM-398) as second-line monotherapy for patients with small cell lung cancer whose disease progressed following a platinum-based chemotherapy regimen.

Investigators hope discovery will lead to new treatments for pancreatic cancer.

Pralsetinib (Gavreto) approved for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer.

Medicaid expansion was associated with a 2% drop in cancer mortality, a recent study found.

In the digital age, exponential technologies are converging and transforming how we engage in health care.

The FDA has granted a breakthrough therapy designation to zanidatamab for the treatment of patients with HER2 gene–amplified biliary tract cancer who have received prior therapy.

To analyze digital images of metastatic tumors of melanoma, the researchers used computer algorithms, or deep convolutional neural networks (DCCN), to identify patterns associated with treatment response.

FDA grants fast track designation to the BTK inhibitor rilzabrutinib for the treatment of patients with immune thrombocytopenia.

Residency programs in specialty pharmacy are relatively new, emerging in response to dramatic growth in the specialty sector.

Researchers hope clinical trials will begin soon to evaluate oral LMTK3 inhibitors across cancer types.

A review of the biologics license application for lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.

PD-L1 IHC 22C3 pharmDx will aid in the identification of patients with triple-negative breast cancer eligible for treatment with pembrolizumab.

Although a single IVIG dose of 25 g was effective in most cases, for some strains repeated doses were necessary to achieve a significant reduction in superantigenic responses.

In the years following the passage of the Affordable Care Act, early-stage cancer diagnosis increased while late-stage fell.

In a trial, 91% of patients rated Sutab as very easy to tolerable to consume, and 78% said they would request Sutab again for a future colonoscopy.

Pharmacists and other medical experts also have a great opportunity to use social media to correct misconceptions, provide guidance, and steer patients toward credible sources.

The FDA approved FoundationOne Liquid CDx as a companion diagnostic with olaparib for certain patients with metastatic castration-resistant prostate cancer.